What is HC Wainwright’s Estimate for UBX FY2025 Earnings?

Unity Biotechnology, Inc. (NASDAQ:UBX) – Stock analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Unity Biotechnology in a research note issued on Monday, March 10th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($1.45) per share for the year, up from their previous estimate of ($1.71). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Unity Biotechnology’s FY2026 earnings at ($0.42) EPS, FY2027 earnings at $0.23 EPS and FY2028 earnings at $0.68 EPS.

Separately, Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Unity Biotechnology in a research note on Monday.

Unity Biotechnology Price Performance

NASDAQ:UBX opened at $1.72 on Wednesday. Unity Biotechnology has a fifty-two week low of $0.94 and a fifty-two week high of $3.10. The stock’s 50-day moving average is $1.87 and its two-hundred day moving average is $1.51. The stock has a market cap of $28.98 million, a PE ratio of -1.31 and a beta of 1.02.

Institutional Investors Weigh In On Unity Biotechnology

An institutional investor recently raised its position in Unity Biotechnology stock. Bridgeway Capital Management LLC boosted its stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) by 100.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,000 shares of the company’s stock after purchasing an additional 25,000 shares during the quarter. Bridgeway Capital Management LLC owned about 0.30% of Unity Biotechnology worth $49,000 at the end of the most recent quarter. 29.49% of the stock is owned by hedge funds and other institutional investors.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.